Editas Medicine· @editasmed · X·· 5 天前AI 评分18
AI 导读
在#AHA2026上,Editas分享了新的临床前数据,展示EDIT-401的持久性。所公布的结果支持EDIT-401作为高脂血症患者变革性疗法的潜力。了解更多:https://bit.ly/4fvsCxB。#invivo
正文
At #AHA2026, Editas shared new preclinical data demonstrating the durability of EDIT-401. The findings presented support EDIT-401’s potential as a transformative therapy for people living with hyperlipidemia. Learn more: https://bit.ly/4fvsCxB. #invivo
来源:Editas Medicine · x.com